問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
陳昱
下載
2025-01-15 - 2032-12-01
Condition/Disease
Test Drug
Participate Sites5Sites
Recruiting5Sites
2025-06-01 - 2028-05-31
Participate Sites11Sites
Recruiting11Sites
2023-02-01 - 2028-01-31
Participate Sites10Sites
Not yet recruiting6Sites
Recruiting4Sites
2023-06-01 - 2028-12-31
-
Participate Sites3Sites
Recruiting3Sites
2023-12-01 - 2027-12-31
Participate Sites9Sites
Recruiting9Sites
2021-09-01 - 2022-11-30
Participate Sites12Sites
Recruiting10Sites
Terminated2Sites
2023-07-07 - 2025-12-31
Non-Small Cell Lung Cancer、 Head and Neck Squamous Cell Carcinoma
ABBV-514ABBV-181 (Budigalimab)
全部
